A5036371212- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Biosimilars and Bioanalytical Methods
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Renal cell carcinoma treatment
- Cervical Cancer and HPV Research
- Radiomics and Machine Learning in Medical Imaging
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- Economic and Financial Impacts of Cancer
- Endometrial and Cervical Cancer Treatments
- Genital Health and Disease
- Neurofibromatosis and Schwannoma Cases
- Gastrointestinal Tumor Research and Treatment
- Neutropenia and Cancer Infections
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Genetic factors in colorectal cancer
- CAR-T cell therapy research
- Medical Imaging and Pathology Studies
- Peptidase Inhibition and Analysis
- Ferroptosis and cancer prognosis
Eastern Cooperative Oncology Group
2024
Santa Casa de Misericórdia de Marília
2008-2023
Irmandade da Santa Casa de Misericórdia de São Paulo
2021
Santa Casa Hospital
2003-2019
Fundação Faculdade de Medicina
2006
BackgroundAfatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade afatinib plus paclitaxel superior outcomes versus switching to chemotherapy alone acquiring resistance erlotinib/gefitinib and monotherapy.Patients methodsPatients relapsed/refractory disease following ≥1 line of chemotherapy, whose tumors had progressed...
Bempegaldesleukin (BEMPEG) is a pegylated interleukin (IL)-2 cytokine prodrug engineered to provide controlled and sustained activation of the clinically validated IL-2 pathway, with goal preferentially activating expanding effector CD8
PF-06439535 is a bevacizumab biosimilar. We aimed to compare the efficacy and safety of with that reference (Avastin®) sourced from EU (bevacizumab-EU), each paclitaxel carboplatin, in first-line treatment advanced non-squamous non-small-cell lung cancer (NSCLC).In this double-blind, parallel-group study, we recruited patients 159 centers 27 countries. Participants were randomized 1:1 receive plus carboplatin or bevacizumab-EU on day 1 21-day cycle for 4-6 cycles, followed by blinded...
A 59-year-old white man was referred for evaluation of epigastric pain that radiating to his back and a 5-kg weight loss over 6 months. computed tomography (CT) scan revealed heterogeneous low-attenuation tumor, measuring 5 cm in size, adjacent the celiac artery pancreatic body ([Fig. 1]). Sectorial endoscopic ultrasound (GF-UCT140-AL5; Olympus America Inc., New York, USA), coupled an unit (Prosound alfa-5 SX; Aloka), detected retroperitoneal well-circumscribed, hypoechoic mass, which...
Purpose The aim of this study was to analyse and quantify the prevalence six comorbidities from lung cancer screening (LCS) on computed tomography (CT) scans patients developing countries. Methods For retrospective study, low-dose CT (n=775) were examined who underwent LCS in a tertiary hospital between 2016 2020. An age- sex-matched control group obtained for comparison (n=370). Using software, coronary artery calcification (CAC), skeletal muscle area, interstitial abnormalities, emphysema,...
LBA7727 Introduction: The mild toxicity profile of pemetrexed (P), seen in a phase III trial P 500 mg/m 2 vs docetaxel 75 vitamin-supplemented patients (pts), suggests higher doses can be given pts with previously treated advanced non-small cell lung cancer (NSCLC) without significant toxicity. We conducted to determine if dose (900 ) could improve survival the standard NSCLC. Methods: Pts stage III/IV NSCLC, platinum-based chemotherapy, were randomized or 900 iv q3week. After second planned...
Abstract Purpose Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed the new era of immunotherapy, and novel strategies are being developed; however, identifying systemic treatments still challenging. This paper presents update expert panel consensus from Latin American Cooperative Oncology Group Cancer on advanced renal management in Brazil. Methods A 34 oncologists experts discussed voted best options for managing Brazil, including...
109 Background: This ongoing, double-blind, randomized, global clinical trial (NCT02364999) evaluated the efficacy, safety, and immunogenicity of PF-06439535 vs. reference bevacizumab sourced from EU (bevacizumab-EU), in combination with paclitaxel (P) carboplatin (C), as first-line therapy patients advanced non-squamous non-small cell lung cancer (NSCLC). Methods: Eligible pts were randomized 1:1 to or bevacizumab-EU plus P/C on Day 1 every 3-week (wk) cycle followed by blinded monotherapy...
5048 Background: Cervical cancer is an important public health problem worldwide. Following skin and breast carcinoma, cervical the third most common among Brazilian women, ranking first in some developing countries. AUC occurs 15–20% of primary neoplasias. Although etiologic factors for squamous cell carcinoma are well defined, its relationship with sexually transmitted disease as HPV established, we still don’t know about causative AUC. The objective this abstract to determine presence...